Contents:

Chapter 1 Executive Summary Key findings Current positioning: competitive outlook 2003 Future performance: growth drivers and resistors 2004–10 Evolution in therapeutic focus: 2004–10 Key issues facing Amgen: 2004–10 Strategic outlook Chapter 2 Company Strategy Introduction to Amgen Assessment of strategic position Strengths Weaknesses Opportunities Threats Therapeutic foci R&D productivity Development opportunities Organic growth Partnerships/licensing Mergers and acquisitions Geographical expansion Implications of financial position Chapter 3 Portfolio And Pipeline Analysis Therapy area focus in 2003 Business development by therapy area Forecast revenue stream, 2004–10 Therapy area forecasts to 2010 Oncology franchise Marketed products R&D compounds Oncology portfolio sales forecasts and forecast revenue growth Hematology franchise Marketed products R&D compounds Hematology portfolio sales forecasts and forecast revenue growth AIID franchise Marketed products R&D compounds AIID portfolio sales forecasts and forecast revenue growth Other products Marketed products R&D compounds Other products sales forecasts and forecast revenue growth Chapter 4 US Strategy, Portfolio and Pipeline US company strategy Introduction to Amgen US marketing strategies US product sourcing strategy US portfolio and pipeline analysis US therapy area focus in 2004 Forecast US revenue stream, 2005–10 Oncology franchise Hematology franchise AIID franchise Other products franchise Chapter 5 Corporate Development Financial position, 2002–03 Profitability, 1999–2003 Revenue growth Cost structure Liquidity, 1999–2003 2003 performance benchmarking Business model clustering according to 2003 cost ratios 2003 growth and investment momentum Key events shaping corporate activity, 2004 Merger and acquisition activity Corporate alliances and deals Regulatory affairs Chapter 6 Appendix: Supporting Data Financial data Exchange rates Methodology for therapy area forecasting List of Tables Table 1: Combined Amgen’s regional sales, 2003 Table 2: Breakdown of Amgen’s ethical sales by therapy area, 2003–04 Table 3: Forecast sales for Amgen’s major therapy areas, 2004–10 Table 4: Amgen’s marketed oncology portfolio Table 5: Estimation of Aranesp’s sales split by therapy area Table 6: Amgen’s oncology R&D pipeline, 2004 Table 7: Forecast sales for Amgen’s oncology portfolio, 2004–10 Table 8: Amgen’s marketed hematology portfolio Table 9: Amgen’s hematology R&D pipeline, 2004 Table 10: Forecast sales for Amgen’s hematology portfolio, 2004–10 Table 11: Amgen’s marketed AIID portfolio Table 12: Amgen’s AIID R&D pipeline, 2004 Table 13: Forecast sales for Amgen’s AIID portfolio, 2003–10 Table 14: Amgen’s other marketed products Table 15: Amgen’s other R&D products, 2004 Table 16: Forecast sales of Amgen’s other products portfolio, 2004–10 Table 17: Breakdown of Amgen’s US ethical sales by therapy area, 2003–04 Table 18: Forecast US sales for Amgen’s major therapy areas, 2004–10 Table 19: Forecast US sales for Amgen’s oncology portfolio, 2004–10 Table 20: Forecast US sales for Amgen’s hematology portfolio, 2004–10 Table 21: Forecast US sales for Amgen’s AIID portfolio, 2004–10 Table 22: Forecast sales of Amgen’s other products portfolio, 2004–10 Table 23: Amgen’s revenues by division, 2002–03 Table 24: Amgen’s operating expenses, 2002–03 Table 25: Summary of Amgen’s historical M&A activity, 2003–04 Table 26: Summary of Amgen’s historical agreements, 2004–05 Table 27: Exchange rates, 2004 List of Figures Figure 1: Competitive positioning of Amgen within the biotechnology market, 2004 Figure 2: Amgen’s growth drivers and resistors, 2004–10 Figure 3: Evolution in therapeutic focus: 2004–10 Figure 4: Amgen’s R&D dependence Figure 5: Assessment of Amgen’s strategic position, 2004 Figure 6: Development of Amgen’s therapeutic strategy, 2005–10 Figure 7: Company’s ethical sales breakdown, 2004 Figure 8: Amgen’s business development by therapy area Figure 9: Forecast sales for Amgen’s major therapy areas, 2005–10 Figure 10: Aranesp provides Amgen access to the US chemotherapy, EU dialysis and EU chemotherapy market segments Figure 11: Combined company’s ethical sales breakdown, 2004 Figure 12: Forecast US sales for Amgen’s major therapy areas, 2005–10 Figure 13: Amgen’s profitability stream, 1999–2003 Figure 14: Amgen’s liquid assets versus total liabilities, 1999–2003 Figure 15: R&D, S,G&A and COGS spend as a proportion of revenue, 2003 Figure 16: Benchmarking of financial strength, 2003